Cresilon Unveils Next Generation TRAUMAGEL for Advanced Bleeding Control
Cresilon Inc., a leading biotechnology company based in Brooklyn, New York, has made headlines by launching the next generation of its revolutionary hemostatic gel, TRAUMAGEL. The new version made its debut at EMS World Expo 2026, held from September 30 to October 1 in Orlando, Florida. This next-gen TRAUMAGEL boasts a more compact form factor designed to enhance usability for first responders.
The innovation comes at a critical time when swift bleeding control can mean the difference between life and death. TRAUMAGEL is known for its plant-based formulation that can stop bleeding in seconds, making it essential for prehospital and emergency care settings. With the newer model, Cresilon has optimized the product design for easier application, allowing users to deploy the gel with just one hand, which is an important consideration during high-pressure emergency situations.
Cresilon's CEO and co-founder, Joe Landolina, emphasized the urgency of bleeding control in trauma situations, stating, "When a trauma patient is severely bleeding, every second matters. We developed next-gen TRAUMAGEL to make it easier for first responders to carry and deploy this life-saving technology in the field, while giving them the same proven bleeding control they already know and trust."
TRAUMAGEL is distinctive as it is the first hemostatic gel delivered in a syringe format, free from the need for any preparation before application. This innovation significantly streamlines emergency response efforts, allowing professionals to act swiftly and effectively during crises. Since its introduction, TRAUMAGEL has been documented in numerous peer-reviewed studies for its efficacy in controlling hemorrhage, particularly in complex traumatic injuries where traditional methods might fail.
Reports from healthcare providers highlight the gel's successful use in managing bleeding during instances where standard interventions were insufficient. Many have noted that with TRAUMAGEL, they experienced quicker blood control, faster application, and enhanced confidence when transporting patients. This positive feedback reinforces Cresilon's commitment to improving outcomes in trauma care.
Representatives from Cresilon were on-site at the EMS World Expo, providing attendees with hands-on demonstrations of the next-generation TRAUMAGEL. The company is committed to ensuring that emergency medical professionals understand the advantages and techniques involved in utilizing their innovative hemostatic solutions.
Cresilon's trajectory is one of notable growth and recognition within the medical technology sector. The company has garnered accolades such as being listed among Fast Company’s World’s 50 Most Innovative Companies, standing out in the medical devices category. They have also been acknowledged as winners of the EMS World Innovation Awards for TRAUMAGEL, cementing their status as pioneers in hemostatic technology.
The company is focused not only on the emergency services market but also aims to expand its innovative capabilities across various fields, including trauma care, biosurgery, and animal health. As they continue to expand their product offerings, Cresilon envisions further strides in saving lives through cutting-edge science.
For more information on TRAUMAGEL and its applications in emergency care settings, interested parties can visit Cresilon's official website. With their state-of-the-art technology, Cresilon is determined to transform the landscape of bleeding control and trauma management, fulfilling their mission to save lives with every product they develop.
Overall, the launch of TRAUMAGEL's next generation marks a significant advancement in prehospital care that emphasizes both ease of use and effectiveness in critical medical situations. Cresilon is poised to lead the charge in innovating solutions that bolster emergency response protocols and enhance patient care.
The innovation comes at a critical time when swift bleeding control can mean the difference between life and death. TRAUMAGEL is known for its plant-based formulation that can stop bleeding in seconds, making it essential for prehospital and emergency care settings. With the newer model, Cresilon has optimized the product design for easier application, allowing users to deploy the gel with just one hand, which is an important consideration during high-pressure emergency situations.
Cresilon's CEO and co-founder, Joe Landolina, emphasized the urgency of bleeding control in trauma situations, stating, "When a trauma patient is severely bleeding, every second matters. We developed next-gen TRAUMAGEL to make it easier for first responders to carry and deploy this life-saving technology in the field, while giving them the same proven bleeding control they already know and trust."
TRAUMAGEL is distinctive as it is the first hemostatic gel delivered in a syringe format, free from the need for any preparation before application. This innovation significantly streamlines emergency response efforts, allowing professionals to act swiftly and effectively during crises. Since its introduction, TRAUMAGEL has been documented in numerous peer-reviewed studies for its efficacy in controlling hemorrhage, particularly in complex traumatic injuries where traditional methods might fail.
Reports from healthcare providers highlight the gel's successful use in managing bleeding during instances where standard interventions were insufficient. Many have noted that with TRAUMAGEL, they experienced quicker blood control, faster application, and enhanced confidence when transporting patients. This positive feedback reinforces Cresilon's commitment to improving outcomes in trauma care.
Representatives from Cresilon were on-site at the EMS World Expo, providing attendees with hands-on demonstrations of the next-generation TRAUMAGEL. The company is committed to ensuring that emergency medical professionals understand the advantages and techniques involved in utilizing their innovative hemostatic solutions.
Cresilon's trajectory is one of notable growth and recognition within the medical technology sector. The company has garnered accolades such as being listed among Fast Company’s World’s 50 Most Innovative Companies, standing out in the medical devices category. They have also been acknowledged as winners of the EMS World Innovation Awards for TRAUMAGEL, cementing their status as pioneers in hemostatic technology.
The company is focused not only on the emergency services market but also aims to expand its innovative capabilities across various fields, including trauma care, biosurgery, and animal health. As they continue to expand their product offerings, Cresilon envisions further strides in saving lives through cutting-edge science.
For more information on TRAUMAGEL and its applications in emergency care settings, interested parties can visit Cresilon's official website. With their state-of-the-art technology, Cresilon is determined to transform the landscape of bleeding control and trauma management, fulfilling their mission to save lives with every product they develop.
Overall, the launch of TRAUMAGEL's next generation marks a significant advancement in prehospital care that emphasizes both ease of use and effectiveness in critical medical situations. Cresilon is poised to lead the charge in innovating solutions that bolster emergency response protocols and enhance patient care.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.